6DFB9EF2-4993-4CF1-B0F7-F8A9409DF3B5
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.299605781865966
- age_years
- 39
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.519
- E2F_TARGETS+0.495
- ALLOGRAFT_REJECTION+0.494
- INTERFERON_ALPHA_RESPONSE+0.433
- INTERFERON_GAMMA_RESPONSE+0.392
- MYC_TARGETS_V2+0.359
- INFLAMMATORY_RESPONSE+0.341
- MYC_TARGETS_V1+0.325
- IL6_JAK_STAT3_SIGNALING+0.283
- MITOTIC_SPINDLE+0.277
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.375
- MYOGENESIS-0.298
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.283
- KRAS_SIGNALING_DN-0.257
- ADIPOGENESIS-0.227
- HYPOXIA-0.151
- FATTY_ACID_METABOLISM-0.125
- PEROXISOME-0.120
- ESTROGEN_RESPONSE_EARLY-0.110
- ESTROGEN_RESPONSE_LATE-0.105
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 33233781-A799-4610-86FC-C836713D31AA | — | — | 0.856 |
| 2 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.850 |
| 3 | 0FCC6761-EFEA-4C47-A36F-9DB187A4649D | — | — | 0.834 |
| 4 | SRR934909 | — | — | 0.822 |
| 5 | SRR934757 | — | — | 0.819 |
| 6 | MNG1210 | — | — | 0.817 |
| 7 | BS_H1ZS5FMZ | high-grade glioma | — | 0.816 |
| 8 | TCGA-83-5908-01A-21R-2287-07 | — | cohortA1 | 0.810 |
| 9 | SRR934821 | — | — | 0.807 |
| 10 | SRR934763 | — | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.519 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.495 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.494 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.433 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.392 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.359 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.341 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.325 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.283 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.277 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.253 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.248 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.237 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.196 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.192 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.182 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.162 | Idelalisib | — uncovered |
| COAGULATION | 0.151 | Binimetinib | — uncovered |